Day: January 3, 2024

EF Hutton Appoints David Sans as Head of Healthcare

Written by Customer Service on January 3, 2024. Posted in Public Companies.

Accomplished healthcare and finance leader brings strategic experience and vision to Healthcare & Life Sciences Investment Banking Team NEW YORK, NY, Jan. 03, 2024 (GLOBE NEWSWIRE) — via NewMediaWire — EF Hutton, an investment bank headquartered in New York, today announced the appointment of David Sans, PhD, FAARM MBA, as Managing Director, Head of Healthcare, to lead the Company’s Healthcare & Life Sciences Investment Banking Team. David Sans, PhD, FAARM MBA, brings many years of biotech and pharma experience in corporate finance, business development, operational, and commercial roles spanning both large pharmaceutical and emerging biotechnology companies. Previously, David served as Head of Market Analytics at Pfizer during the launch of Rebif® (interferon beta-1a for MS) and Macugen® (pegaptanib) and as...

Tap offering of UAB „Atsinaujinančios energetikos investicijos“ bonds under the EUR 100 million Green Bonds Programme

Written by Customer Service on January 3, 2024. Posted in Public Companies.

UAB “Atsinaujinančios energetikos investicijos” (the Company) has started accepting subscriptions for a tap offering under its EUR 100 milion Green Bonds Programme (ISIN – LT0000405938). The Company is planning to issue up to EUR 18.9 million of nominal value bonds to investors in Lithuania, Latvia and Estonia with a yield-to-maturity of 10.00% and clean issue price of 91.573055%. With the issuance of an additional EUR 18.9 million of nominal value bonds, the aggregate total value of bonds issued under the Green Bonds Programme will be EUR 91.3 million. The offering period during which the bonds can be subscribed starts on 3 January 2024 and ends on 18 January 2024 3:00 PM (EET). The bonds’ trading date is 18 January 2024 and settlement date is 24 January 2024 (T+4). More information about the bond issue can be found on the Company’s...

For Calendar Year 2023, Mullen Hits Class 3 Delivery Target with 141 Class 3’s Delivered to RMA; Total Invoiced Amount of $9,196,021

Written by Customer Service on January 3, 2024. Posted in Public Companies.

For 2023, Company built 154 Class 3’s and delivered 141 units to RMAFor 2023, Company has delivered 141 Mullen THREE’s, Class 3 EV Trucks to RMARandy Marion Automotive (“RMA”) is one of the top commercial dealer groups in the U.S.BREA, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) — via IBN — Mullen Automotive, Inc. (NASDAQ: MULN) (“Mullen” or the “Company”), an emerging electric vehicle (“EV”) manufacturer, today announces that for calendar year 2023 Mullen achieved its previously announced Class 3 target with 154 Class 3’s built and 141 Class 3’s delivered to Randy Marion Automotive Group (“RMA” or “Randy Marion”) for a total invoiced amount of $9,196,021. The remaining 13 vehicles are being utilized for engineering and marketing purposes. Mullen THREE production is based out of Tunica, Mississippi,...

Piedmont Federal Savings Bank Announces Completion of Acquisition of Wake Forest Bancshares, Inc.

Written by Customer Service on January 3, 2024. Posted in Mergers And Acquisitions.

WINSTON-SALEM, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) — Piedmont Financial Holding Company, the parent company of Piedmont Federal Savings Bank (“Piedmont Federal”), has announced the completion of its acquisition of Wake Forest Bancshares, Inc. (OTC Pink: WAKE), the parent company of Wake Forest Federal Savings and Loan Association (“Wake Forest Federal”). Piedmont Federal was chartered in 1903 and serves clients in markets ranging from the Northwest Piedmont to the Triad and Lake Norman. Its merger with Wake Forest Federal, founded in 1922, has extended its deposit client base to include Wake Forest Federal’s office located in the heart of Wake Forest, NC, which will continue to operate as “Wake Forest Federal, a division of Piedmont Federal,” for the foreseeable future. Per the terms of the transaction, minority shareholders...

FK Distribution acquires and takes charge of Aviou software technology

Written by Customer Service on January 3, 2024. Posted in Mergers And Acquisitions.

Investor News 3 January 2024 With effect from 1 January 2024, FK Distribution, the owner of the minetilbud digital offers platform, has acquired and taken charge of Aviou’s business operations involving the publication of online catalogues and offers. The investment is a part of FK Distribution’s strategy to strengthen minetilbud’s position as Denmark’s largest special offers platform by providing new digital offer formats to its 1.6 million plus users. By adding Aviou’s technology, FK Distribution – the largest subsidiary of the North Media Group – is executing on its strategy to strengthen minetilbud’s market position. Currently, the platform has more than 1.6 million users and in excess of 100 million annual reads of digital leaflets and online offers from customers in the retail and e-commerce segments. Aviou’s technology consists...

G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Written by Customer Service on January 3, 2024. Posted in Public Companies.

RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Chief Executive Officer Jack Bailey will provide a corporate presentation during the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024, at 1:30 PM PST. The webcast of the event will be accessible on the Events & Presentations page of http://www.g1therapeutics.com. About G1 TherapeuticsG1 Therapeutics, Inc. is a commercial-stage oncology biopharmaceutical company whose mission is to develop and deliver next-generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA® (trilaciclib). The Company is also evaluating therapies in combination with cytotoxic therapies and/or immunotherapy...

Baltic Horizon Fund financial calendar for 2024

Written by Customer Service on January 3, 2024. Posted in Public Companies.

Baltic Horizon Fund intends to disclose financial results and arrange the general meeting of unit-holders and Swedish Depositary Receipt holders (hereinafter together the “Investors”) according to the following schedule in 2024:Interim Financial Statements for 12 months of 2023 15 February 2024Audited annual report for 2023 28 March 2024Audited annual report for 2023 of the management company Northern Horizon Capital AS 25 April 2024Interim Financial Statements for 3 months of 2024 9 May 2024Annual General Meeting of Investors 3 June 2024Interim Financial Statements for 6 months of 2024 8 August 2024Interim Financial Statements for 9 months of 2024 ...

Baltic Horizon Fund financial calendar for 2024

Written by Customer Service on January 3, 2024. Posted in Public Companies.

Stabilisation transactions with AS Infortar shares from 28.12.2023 to 03.01.2024

Written by Customer Service on January 3, 2024. Posted in Public Companies.

This notice is published with reference to the initial public offering of the shares of AS Infortar (“Infortar”) and should be read in conjunction with Infortar’s public offering, listing and admission to trading prospectus dated 24 November 2023 (the “Prospectus”), together with Infortar’s notification on the results of the initial public offering of its shares and final price dated 11 December 2023. Infortar informs that on period commencing on 28 December 2023 and ending on 03 January 2024 (both included) the following stabilisation measures on following conditions were carried out by Swedbank AS as the Stabilising Arranger: Company: AS InfortarSecurities: INFORTAR LIHTAKTSIA, ISIN code: EE3100149394Ticker: INF1TStabilising Arranger: Swedbank ASTrading Venue: Nasdaq Tallinn Stock ExchangeStabilisation Period Start...

Sanara MedTech Inc. Announces Exclusive License Agreement for Patented Collagen Peptides

Written by Customer Service on January 3, 2024. Posted in Public Companies.

FORT WORTH, TX, Jan. 03, 2024 (GLOBE NEWSWIRE) — Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), announced today that is has signed an exclusive license agreement with Tufts University (“Tufts”) to develop and commercialize patented technology covering 18 unique collagen peptides. Zach Fleming, Sanara’s CEO stated, “Sanara has established itself as a leader in bioactive collagen peptides with CellerateRX® Surgical Powder (“CellerateRX”). We see significant opportunities to broaden our existing CellerateRX product line and develop new bioactive collagen peptide-based applications that will help improve outcomes and advance patient care while reducing healthcare system costs. We believe that the technology that we have licensed from Tufts, supported...

Day: January 3, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice